about
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience.Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.MET and ALK as targets for the treatment of NSCLC.Targeting the MET gene for the treatment of non-small-cell lung cancer.MET and Small-Cell Lung Cancer.Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?FGFR as potential target in the treatment of squamous non small cell lung cancer.The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer.Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer.Clinical implications and future perspectives in testing non-small cell lung cancer (NSCLC) for anaplastic lymphoma kinase (ALK) gene rearrangements.Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC.EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer.Asymptomatic pulmonary embolism in lung cancer: prevalence and analysis of clinical and radiological characteristics in 141 outpatientsAccuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung CancerFatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancerDo we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?
P50
Q33892582-533F9F1A-45E4-4F93-9CA5-427A85825894Q37952233-32F5C14E-7363-4F87-84EC-1590362F3385Q37952236-56CB50AA-B77E-452C-9108-27D2246A4C91Q38153827-85312CA6-0C3C-4CBA-8ADA-4217C37DA2CAQ38172700-699A0759-5285-4BA6-88B2-DA0DB89A7372Q38260120-95914BF0-228B-4248-8CB6-2936F13A5302Q38293725-4614BD4C-542C-444F-8A85-16FD35B9D629Q38435145-1393A6BB-6819-4373-A9E5-5BD06C11B328Q38470406-36EE90E4-9FC9-4865-982A-0AF6E9E9CC28Q38841082-EB96B59B-DBB6-4C00-9AB0-46394D777C06Q38863105-B4EA2EF0-C556-4438-8DE7-9AFFC50B2834Q39013047-1150B25D-660C-4680-8CD2-889171269F9CQ44407561-60D404B8-A9FC-4B3F-BF5A-CDE81042D13BQ52983636-9CACF8A0-09C2-4CF8-B46B-BB8E4F0DB921Q53281945-6B860649-C30B-40F9-BDB4-13081B98BAEAQ54582444-9FB9985D-C7CA-49EE-A5BF-C16611FAFB35Q57725981-799A7010-8086-421C-8F95-CF09D51AC367Q57762661-06C6359C-44FE-45FA-B91F-9CAC99042DF3Q57763406-5CD3A044-8017-4C55-861E-3A7DA17FAC2AQ87227033-69D7103D-5072-4479-ACCE-B008B369337C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
F Gelsomino
@ast
F Gelsomino
@en
F Gelsomino
@es
F Gelsomino
@nl
F Gelsomino
@sl
type
label
F Gelsomino
@ast
F Gelsomino
@en
F Gelsomino
@es
F Gelsomino
@nl
F Gelsomino
@sl
prefLabel
F Gelsomino
@ast
F Gelsomino
@en
F Gelsomino
@es
F Gelsomino
@nl
F Gelsomino
@sl
P106
P31
P496
0000-0001-9286-1913